Reistone Biopharma Company Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Reistone Biopharma Company Limited
Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.
Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance
US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.
The Turkish pharmaceutical market reached $5.6bn in 2017. Despite strong competition from multinationals, Abdi Ibrahim, a local company, was market leader last year with a turnover of $380m. It was followed by Novartis and Pfizer.
Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?